Zanamivir
Zanamivir is a neuraminidase inhibitor that competitively blocks the influenza virus neuraminidase enzyme, preventing cleavage of sialic acid from host cell surface glycoproteins and inhibiting viral release, spread, and penetration of respiratory mucus. It is inhaled via the Diskhaler device for treatment and prevention of influenza A and B infections. Its topical inhalation route limits systemic bioavailability while delivering high drug concentrations to the respiratory tract.
Masse moléculaire
332,3100 g/mol
LogP
-3,20
TPSA
201,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N
InChI
InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
Molecular Formula
C12H20N4O7
HBD / HBA
7 / 8
Liaisons Rotatives
6
Atomes Lourds
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Zanamivir is a neuraminidase inhibitor that competitively blocks the influenza virus neuraminidase enzyme, preventing cleavage of sialic acid from host cell surface glycoproteins and inhibiting viral release, spread, and penetration of respiratory mucus. It is inhaled via the Diskhaler device for treatment and prevention of influenza A and B infections. Its topical inhalation route limits systemic bioavailability while delivering high drug concentrations to the respiratory tract.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Zanamivir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL222813. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60855. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="zanamivir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/zanamivir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/zanamivir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/zanamivir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="zanamivir"></drugfyi-drug>